Sharemaestro company-news research for ProMIS Neurosciences Inc. (PMN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest PMN news and sentiment

ProMIS Neurosciences Inc.

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research RSS feed
30-day score50Neutral is 50
Early balanced news score 16/100 evidence confidence 100% direct company focus 9 current stories across 2 publishers
Latest weekly closeUSD 13.56week of 11 Sep 2026
Main news subjectEarnings81/100 share of current news
News data statusPartial18 duplicate stories removed

Current company news

Early balanced news score

9 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone53/100 Published 30-day score50/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline ProMIS Neurosciences at Moody Capital conference: safety sets it apart By Investing.com Investing.com Canada · 10 Sep 2026 18:36

What supports the score

Direct evidence

9 current stories are mapped specifically to PMN.

What limits the score

Source breadth

Only 2 publishers currently contribute to the measured read.

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.015.

Confidence

Confidence is 16/100, below the threshold for a firm score.

50/100
News scoreEarly balanced news score
16/100
Confidencethin evidence
100%/100
Company news9 company stories
85/100
Story agreement15/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
19 Aug: 2 stories23 Aug: 1 stories24 Aug: 1 stories30 Aug: 2 stories01 Sep: 1 stories09 Sep: 1 stories10 Sep: 1 stories 19 Aug: tone 68, 2 stories23 Aug: tone 50, 1 stories24 Aug: tone 50, 1 stories30 Aug: tone 43, 2 stories01 Sep: tone 50, 1 stories09 Sep: tone 50, 1 stories10 Sep: tone 50, 1 stories 95505
18 Aug02 Sep16 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence0
0.015 after freshness weighting
Source breadth40
2 independent publishers
Company relevance100
share tied directly to this company
Freshness23
recency-weighted evidence
Agreement85
how closely stories agree
Publisher mix41
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks12 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
20 Mar 2026: close 17.6, indexed 100.027 Mar 2026: close 14.74, indexed 83.703 Apr 2026: close 12.51, indexed 71.110 Apr 2026: close 12.6, indexed 71.617 Apr 2026: close 11.53, indexed 65.524 Apr 2026: close 11.24, indexed 63.901 May 2026: close 11.01, indexed 62.608 May 2026: close 9.83, indexed 55.915 May 2026: close 10.39, indexed 59.022 May 2026: close 10.98, indexed 62.429 May 2026: close 10.81, indexed 61.405 Jun 2026: close 9.13, indexed 51.912 Jun 2026: close 10.35, indexed 58.819 Jun 2026: close 10.54, indexed 59.926 Jun 2026: close 10.53, indexed 59.803 Jul 2026: close 13.35, indexed 75.910 Jul 2026: close 14.25, indexed 81.017 Jul 2026: close 15.19, indexed 86.324 Jul 2026: close 12.2, indexed 69.331 Jul 2026: close 13.72, indexed 78.007 Aug 2026: close 14.71, indexed 83.614 Aug 2026: close 14.86, indexed 84.421 Aug 2026: close 14.51, indexed 82.428 Aug 2026: close 13.785, indexed 78.304 Sep 2026: close 12.6, indexed 71.611 Sep 2026: close 13.56, indexed 77.0 26 Jun 2026: news score 50, close 10.53, 2 stories5003 Jul 2026: news score 50, close 13.35, 3 stories10 Jul 2026: news score 52, close 14.25, 5 stories5217 Jul 2026: news score 53, close 15.19, 9 stories24 Jul 2026: news score 51, close 12.2, 9 stories5131 Jul 2026: news score 59, close 13.72, 31 stories07 Aug 2026: news score 53, close 14.71, 42 stories5314 Aug 2026: news score 59, close 14.86, 52 stories21 Aug 2026: news score 55, close 14.51, 55 stories5528 Aug 2026: news score 52, close 13.785, 35 stories04 Sep 2026: news score 50, close 12.6, 29 stories5011 Sep 2026: news score 50, close 13.56, 26 stories50 Price index 105.8 75.9 46.1 News score 100 50 0
20 Mar16 Jun11 Sep
Weekly close, indexedSentiment score
26-week price-23.0%latest close 13.56
News score change+0first to latest comparable week
One-week response+7.6%Price confirming higher
Fair-value position-45.4%Below fair value
WeekNews scoreCloseWeekly move
11 Sep 202650USD 13.56+7.6%
04 Sep 202650USD 12.6-8.6%
28 Aug 202652USD 13.785-5.0%
21 Aug 202655USD 14.51-2.4%
14 Aug 202659USD 14.86+1.0%
07 Aug 202653USD 14.71+7.2%
31 Jul 202659USD 13.72+12.5%
24 Jul 202651USD 12.2-19.7%
Provisional evidence

News subjects

What is shaping the score

Earnings
Earnings516 stories · 67%
Market update503 stories · 33%

Source mix

Where the evidence comes from

41/100 independence
Value Research432 stories · 22%
siam.in751 stories · 11%
MarketBeat551 stories · 11%
Investing.com Canada501 stories · 11%
Kalkine501 stories · 11%
Yahoo! Finance Canada501 stories · 11%
Vinanet501 stories · 11%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences4Financial Markets3Earnings3Finance1

Earlier readings

How the score has changed

32 comparable readings · 83 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+050 to 50 · Broadly stable
Observed range50–6050 is the neutral baseline
Evidence depth9stories at latest stored reading · +8
Confidence15/100Provisional · +15
24 Jun50 neutral15 Sep 12:04
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
15 Sep 12:0450+015/100 (-2)9 (-17)Provisional
10 Sep 23:5950+017/100 (0)26 (+1)Provisional
09 Sep 23:5950-117/100 (-5)25 (-8)Provisional
01 Sep 23:5951+022/100 (-3)33 (-2)Provisional
30 Aug 23:5951-325/100 (+1)35 (-19)Provisional
24 Aug 23:5954+024/100 (-2)54 (-2)Provisional
23 Aug 23:5954-326/100 (-8)56 (+1)Provisional
19 Aug 23:5957+034/100 (-7)55 (+1)Provisional

Source headlines

The news behind the score

Showing 1-9 of 9

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
Investing.com CanadaDirect company coverageStored article

ProMIS Neurosciences at Moody Capital conference: safety sets it apart By Investing.com

ProMIS Neurosciences presented encouraging interim safety and biomarker data for its Alzheimer's drug candidate, PMN310, at the Moody Capital Disruptive Growth & Life Science Conference. The company highlighted PMN310's clean safety profile with zero ARIA-E cases, contrasting it with competitors, and reported a 15% reduction in p-tau217, a key Alzheimer's biomarker. ProMIS believes its platform, which targets only toxic beta-amyloid oligomers, provides a differentiated approach and positions the company for a potential direct Phase 3 registration path.

EarningsFinancial MarketsLife Sciences
Published
10 Sep 2026 18:36
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 5.8d old
Duplicates
1 consolidated
#3—Not directional
Yahoo! Finance CanadaDirect company coverageStored article

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

ProMIS Neurosciences Inc. (Nasdaq: PMN) announced its participation in several September 2026 conferences and investor events, including the Cantor Global Healthcare Conference, Moody Capital Disruptive Growth & Life Sciences Conference, and H.C. Wainwright 28th Annual Global Investment Conference. Company leaders will discuss their EpiSelect™ platform, therapeutic approach for neurodegenerative diseases, and PMN310, their lead candidate for early Alzheimer's disease. The company also plans to mark World Alzheimer's Day at the Nasdaq Tower.

Life Sciences
Published
01 Sep 2026 12:14
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 15.0d old
Duplicates
2 consolidated
#4—Not directional
Value ResearchDirect company coverageScored from headline

ProMIS Neurosciences Inc. (PMN) Peer Comparison – Compare with Others

Published
30 Aug 2026 04:17
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 17.4d old
Duplicates
1 consolidated
#6—Not directional
VinanetDirect company coverageScored from headline

ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71% - Revenue Estimate Trend

Published
24 Aug 2026 21:43
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 22.6d old
Duplicates
1 consolidated
#7—Not directional
Simply Wall StreetDirect company coverageStored article

ProMIS Neurosciences (Nasdaq:PMN) - Stock Analysis

This Simply Wall St analysis provides an overview of ProMIS Neurosciences (PMN), highlighting its market cap of US$130.1m and recent performance. The article details the company's lead drug candidate, PMN310, for Alzheimer's disease, including positive interim safety and biomarker data from its Phase 1b trial and previous human evidence of target engagement. It also discusses various financial risks such as declining earnings forecasts, shareholder dilution, and a low market capitalization.

EarningsFinancial MarketsLife Sciences
Published
23 Aug 2026 20:14
News subject
Earnings
Why this score
Dilution risk
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 23.7d old
Duplicates
1 consolidated
#8—Not directional
MarketBeatDirect company coverageStored article

Q3 EPS Estimates for PMN Raised by Brookline Capital Markets

Brookline Capital Markets has raised its Q3 2026 EPS forecast for Promis Neurosciences (NASDAQ:PMN) to a loss of $1.29 per share from a previous estimate of $2.41, while maintaining a "Strong Buy" rating. The company recently reported a quarterly loss of $1.28 per share, outperforming the consensus estimate. Promis Neurosciences currently holds a "Moderate Buy" consensus rating among analysts with an average target price of $31.50.

EarningsFinanceFinancial MarketsLife Sciences
Published
19 Aug 2026 12:12
News subject
Earnings
Why this score
Guidance raised
Company focus
Company discussed · 86%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 28.0d old
Duplicates
1 consolidated

Earlier company news

PMN news archive

67 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 67 older PMN headlines. Open one page at a time when you need them.

Open older archive

Provider matches checked

Provider mentions not used in the score

3 not scored

A news provider linked these stories to PMN, but the headline and available text are not mainly about ProMIS Neurosciences Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of PMN sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context